Factory Supply Alogliptin Benzoate CAS 850649-62-6 Alogliptin for Type 2 Diabetes

Allogliptin (US trade name: Nesina, European trade name: Vipidia) is an oral DPP-4 inhibitor anti diabetes drug. Alogliptin is the most selective marketed DPPIV inhibition and has similar PK and PD properties compared to previous entries. Like other members of the gliptin family, it almost does not lead to weight gain or no weight gain. The risk of hypoglycemia is relatively small, and it shows relatively mild hypoglycemic activity.

Agliptin is a highly selective dipeptidyl peptidase-4 (DPP-4) inhibitor, and its benzoate salt can enhance solubility and stability. By inhibiting DPP-4 enzyme, the degradation of glucagon like peptide-1 (GLP-1) is delayed, secretion is increased, and glucagon release is inhibited, reducing blood sugar without increasing weight/hypoglycemia risk.
Alagliptin benzoate is a safe choice for combination therapy of type 2 diabetes mellitus, with low cardiovascular risk and wide applicability to the general population. However, caution should be taken against joint pain and pancreatitis signals, and dosage adjustment is necessary for patients with renal insufficiency.